Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Boston Sci, Stryker Prevail In Long-Running Suits

Executive Summary

Two closely watched device-world intellectual property cases moved toward a conclusion last week, as Boston Scientific triumphed over Edwards in a TAVR suit and Zimmer was ordered to pay $254m for infringing Stryker’s patent on a surgical-cleaning wand.

You may also be interested in...

Edwards Pays Boston Scientific $180M In TAVR Patent Settlement

Edwards Lifesciences and Boston Scientific announced this week that the firms had resolved an ongoing global patent dispute.

German Court Rules For Boston Scientific In TAVR Patent Tiff

A German court has issued a preliminary ruling favoring Boston Scientific in its most recent intellectual property dispute with Edwards LifeSciences. The ruling would allow Boston Scientific to block Edwards’ Sapien 3 Ultra from the German market.

Judge Rules For Enhanced Damages In Zimmer-Stryker Patent Spat

The case had gone to the US Supreme Court due to a dispute over the standards for enhanced damages. Zimmer, which was ordered to pay almost $250m in costs and penalties, expects to appeal the verdict.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts